fluorobenzenes has been researched along with Inflammatory Response Syndrome, Systemic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ballerio, R; Banfi, C; Blanc-Guillemaud, V; Brioschi, M; Castiglioni, L; Gelosa, P; Gianella, A; Guerrini, U; Lerond, L; Nobili, E; Pignieri, A; Sironi, L; Tremoli, E | 1 |
1 other study(ies) available for fluorobenzenes and Inflammatory Response Syndrome, Systemic
| Article | Year |
|---|---|
Terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, increases survival in stroke-prone rats by preventing systemic inflammation and endothelial dysfunction: comparison with aspirin and rosuvastatin.
Topics: Animals; Aspirin; Biomarkers; Blood Pressure; Brain; Endothelium, Vascular; Fluorobenzenes; Hypertension; Magnetic Resonance Imaging; Male; Naphthalenes; Propionates; Protective Agents; Pyrimidines; Rats; Rats, Inbred SHR; Receptors, Prostaglandin; Receptors, Thromboxane; Rosuvastatin Calcium; Stroke; Sulfonamides; Survival Analysis; Systemic Inflammatory Response Syndrome | 2010 |